BEAM
BEARISH
$31.56
Live
Beam Therapeutics Inc. · NASDAQ
Target $45.47
(+44.1%)
$13.53
52W Range
$36.44
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$3.2B
P/E
N/A
ROE
-47.2%
Profit margin
N/A
Debt/Equity
0.16
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
65%
The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 1/9, indicating severe operational and profitability concerns. Despite a strong analyst recommendation of 'strong_buy' and a target price implying 44% upside, the company exhibits negative gross and operating margins, deteriorating revenue growth, and deeply negative returns on equity and assets. Insider selling activity totaling $3.19M over the past six months contradicts the bullish analyst sentiment, while valuation multiples like a Price/Sales ratio of 57.50 are extremely stretched relative to fundamentals. Although the current ratio is strong at 6.02, suggesting near-term liquidity safety, the lack of Altman Z-Score and persistent unprofitability elevate long-term sustainability risks.
Key Strengths
Exceptionally strong liquidity position with a current ratio of 6.02 and quick ratio of 5.89, providing runway for R&D and operations
Low debt burden with a Debt/Equity ratio of 0.16, well below sector average of 2.71, reducing financial risk
Analyst consensus is strongly bullish with a 'strong_buy' rating from 15 analysts and a mean target price of $45.47
Recent price momentum is positive, with +45.3% return over the last 6 months and +20.1% over the past year
Peer group context shows BEAM's financial struggles are not isolated, as biotech sector averages include negative ROE and profit margins
Key Risks
Critically low Piotroski F-Score of 1/9 signals severe financial distress and poor fundamental strength
Operating margin of -1307.60% and gross margin of 0.00% indicate no viable path to profitability in the near term
Revenue growth is sharply negative at -32.00% YoY, reversing prior growth trends and signaling weakening commercial momentum
Insiders have been net sellers with $3.19M in sales over the last 6 months and zero buy transactions, suggesting lack of confidence
Extremely high valuation metrics — Price/Sales of 57.50 and negative Forward P/E of -6.85 — imply speculative pricing with no earnings support
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
16
Weak
15
30
25
10
0
AI Verdict
Highly speculative with weak fundamentals and elevated risk
Key drivers: Piotroski F-Score of 1/9, Negative operating and gross margins, Insider selling trend, Extremely high Price/Sales ratio, Analyst target price significantly above current valuation
Confidence
70%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
No standout positives identified.
Watchpoints
- Price/Sales of 57.50 is extremely high
- Forward P/E of -6.85 indicates negative earnings
- Price/Book of 3.22 lacks support from profitability
- No Graham Number or Intrinsic Value available
Future
30/100
Ref Growth rates
Positives
- Analyst target price implies significant upside
- Sector peers show high revenue growth potential
Watchpoints
- Revenue growth YoY is -32.00%
- Earnings growth lacks consistency
- No clear path to profitability
Past
25/100
Ref Historical trends
Positives
- Some quarters beat EPS estimates (e.g., +343.6% surprise in Q1 2024)
Watchpoints
- Frequent and large negative earnings surprises
- Long history of negative EPS
- Revenue growth has reversed into decline
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 6.02 indicates short-term liquidity
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial weakness
- ROE of -47.19% and ROA of -23.48%
- Operating margin of -1307.60%
- No Altman Z-Score reported
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- Dividend strength score of 0/100
- Payout ratio is 0.00% due to lack of earnings
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$31.56
Analyst Target
$45.47
Upside/Downside
+44.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BEAM and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BEAM
Beam Therapeutics Inc.
Primary
|
-69.2% | -29.2% | +20.1% | +45.3% | +12.2% | +1.1% |
|
ICUI
ICU Medical, Inc.
Peer
|
-38.8% | -28.3% | -9.2% | +10.1% | -6.0% | +1.9% |
|
BKD
Brookdale Senior Living Inc.
Peer
|
+153.4% | +367.5% | +163.2% | +72.4% | +18.9% | +6.2% |
|
KNSA
Kiniksa Pharmaceuticals International, plc
Peer
|
+154.6% | +305.7% | +103.1% | +7.4% | -4.7% | +2.7% |
|
LEGN
Legend Biotech Corporation
Peer
|
-34.7% | -64.1% | -41.9% | -42.7% | -10.4% | -5.1% |
BEA
Beam Therapeutics Inc.
Primary
5Y
-69.2%
3Y
-29.2%
1Y
+20.1%
6M
+45.3%
1M
+12.2%
1W
+1.1%
ICU
ICU Medical, Inc.
Peer
5Y
-38.8%
3Y
-28.3%
1Y
-9.2%
6M
+10.1%
1M
-6.0%
1W
+1.9%
BKD
Brookdale Senior Living Inc.
Peer
5Y
+153.4%
3Y
+367.5%
1Y
+163.2%
6M
+72.4%
1M
+18.9%
1W
+6.2%
KNS
Kiniksa Pharmaceuticals International, plc
Peer
5Y
+154.6%
3Y
+305.7%
1Y
+103.1%
6M
+7.4%
1M
-4.7%
1W
+2.7%
LEG
Legend Biotech Corporation
Peer
5Y
-34.7%
3Y
-64.1%
1Y
-41.9%
6M
-42.7%
1M
-10.4%
1W
-5.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-6.85
PEG Ratio
N/A
P/B Ratio
3.22
P/S Ratio
57.5
EV/Revenue
39.34
EV/EBITDA
-4.93
Market Cap
$3.2B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-1307.6%
Gross Margin
N/A
ROE
-47.19%
ROA
-23.48%
Growth
Revenue and earnings growth rates
Revenue Growth
-32.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.16
Low debt
Current Ratio
6.02
Strong
Quick Ratio
5.89
Excellent
Cash/Share
$10.89
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-24
$N/A
2025-11-04
$-1.1
-8.9% surprise
2025-08-05
$-1.0
+8.4% surprise
2025-05-06
$-1.24
-5.9% surprise
Healthcare Sector Comparison
Comparing BEAM against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-47.19%
This Stock
vs
-88.14%
Sector Avg
-46.5%
(Below Avg)
Debt to Equity
0.16
This Stock
vs
2.66
Sector Avg
-94.1%
(Less Debt)
Revenue Growth
-32.0%
This Stock
vs
124.04%
Sector Avg
-125.8%
(Slower)
Current Ratio
6.02
This Stock
vs
4.47
Sector Avg
+34.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BEAM
Beam Therapeutics Inc.
|
BEARISH | $3.2B | - | -47.2% | -% | $31.56 | |
|
ICUI
ICU Medical, Inc.
|
BEARISH | $3.14B | 4189.33 | 0.0% | 0.0% | $125.68 | Compare |
|
BKD
Brookdale Senior Living Inc.
|
BEARISH | $3.08B | - | -212.3% | -9.9% | $12.95 | Compare |
|
KNSA
Kiniksa Pharmaceuticals...
|
NEUTRAL | $3.34B | 58.15 | 11.7% | 8.7% | $43.61 | Compare |
|
LEGN
Legend Biotech Corporation
|
BEARISH | $3.36B | - | -29.1% | -28.8% | $18.16 | Compare |
BEAM
Beam Therapeutics Inc.
BEARISH
Mkt Cap
$3.2B
P/E
-
ROE
-47.2%
Price
$31.56
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-20 | CAVANAGH BETHANY J | Officer and Treasurer | Sale | 3,034 | $91,384 |
| 2026-01-15 | BELLON CHRISTINE | Officer | Sale | 18,629 | $644,832 |
| 2025-12-31 | SIMON AMY | Officer | Stock Award | 12,500 | - |
| 2025-12-31 | EMANY SRAVAN KUMAR | Chief Financial Officer | Sale | 6,294 | $170,567 |
| 2025-12-31 | BELLON CHRISTINE | Officer | Sale | 1,254 | $33,983 |
| 2025-10-27 | FMR, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | 459 | $12,246 |
| 2025-10-06 | FMR, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Gift | 1,232,434 | - |
| 2025-10-02 | EVANS JOHN M. | Chief Executive Officer | Option Exercise | 50,000 | $33,500 |
| 2025-10-02 | EVANS JOHN M. | Chief Executive Officer | Sale | 50,000 | $1,228,322 |
| 2025-10-01 | BELLON CHRISTINE | Officer | Sale | 373 | $9,150 |
| 2025-10-01 | CAVANAGH BETHANY J | Officer and Treasurer | Sale | 467 | $11,456 |
| 2025-07-30 | FMR, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | 48,374 | $991,667 |
CAVANAGH BETHANY J
Officer and Treasurer
2026-01-20
3,034 shares
·
$91,384
BELLON CHRISTINE
Officer
2026-01-15
18,629 shares
·
$644,832
SIMON AMY
Officer
2025-12-31
12,500 shares
EMANY SRAVAN KUMAR
Chief Financial Officer
2025-12-31
6,294 shares
·
$170,567
BELLON CHRISTINE
Officer
2025-12-31
1,254 shares
·
$33,983
FMR, L.L.C.
Beneficial Owner of more than 10% of a Class of Security
2025-10-27
459 shares
·
$12,246
FMR, L.L.C.
Beneficial Owner of more than 10% of a Class of Security
2025-10-06
1,232,434 shares
EVANS JOHN M.
Chief Executive Officer
2025-10-02
50,000 shares
·
$33,500
EVANS JOHN M.
Chief Executive Officer
2025-10-02
50,000 shares
·
$1,228,322
BELLON CHRISTINE
Officer
2025-10-01
373 shares
·
$9,150
CAVANAGH BETHANY J
Officer and Treasurer
2025-10-01
467 shares
·
$11,456
FMR, L.L.C.
Beneficial Owner of more than 10% of a Class of Security
2025-07-30
48,374 shares
·
$991,667
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
15 analysts
Bernstein
2026-01-21
Outperform
Outperform
UBS
2026-01-07
Neutral
Evercore ISI Group
2025-11-24
Outperform
HC Wainwright & Co.
2025-10-10
Buy
Buy
JP Morgan
2025-10-09
Overweight
Overweight
HC Wainwright & Co.
2025-09-15
Buy
Buy
Barclays
2025-08-06
Equal-Weight
Equal-Weight
Past News Coverage
Recent headlines mentioning BEAM from our newsroom.
Newest → oldest
No matching news yet.